Image-Guided Radiation Therapy Market By Product (4D RT, LINAC, MRI-guided Radiotherapy, Portal Imaging, CT Scanning), By Procedure (IMRT (intensity modulation radiation therapy), Stereotactic Therapy, Particle Therapy, Others) By End User (Hospitals, Independent Radiotherapy Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

July 2024 | 260 pages | ID: I5FB50E2EDE9EN
Allied Market Research

Abstracts

Image-guided Radiation Therapy Market

The image-guided radiation therapy market was valued at $1.9 billion in 2023 and is projected t%li%reach $3.3 billion by 2033, growing at a CAGR of 5.7% from 2024 t%li%2033.

Image-guided radiation therapy is a frequent imaging process used in the treatment of cancer. The therapy involves several imaging techniques such as MRI, PET, and CT scans, which allow for precise targeting of radiation for killing the cancer cells. The precise targeting is performed using the high-quality images generated by imaging technologies. This approach elevates the accuracy of treatment, improves therapy outcomes, and reduces radiation-related complications, making image-guided radiation therapy a necessary procedure in modern oncology practice.

Increase in prevalence of diverse forms of cancers and rise in demand for targeted cancer treatment are the major drivers of the image-guided radiation therapy market. In addition, the deployment of real-time imaging during ongoing treatment sessions has boosted the efficacy of treatment, thereby boosting the demand for image-guided radiation therapy. Surface-guided radiation therapy has recently witnessed widespread adoption in several oncology facilities due t%li%its cutting-edge attributes such as intra-fraction motion monitoring and respiratory gating.

However, the cost associated with procuring instruments related t%li%image-guided radiation therapy, along with the high costs of treatment for the patients, is a major restraint for the market. On the contrary, enhancements in technology are diversifying the prospects of the therapy and refining the healing process. Assimilation of AI and ML is enabling the delivery of personalized cancer treatment according t%li%the vitals and requirements of the patient. For instance, in the case of a patient suffering from glioblastoma, an AI-based dose optimization software was used t%li%tailor the radiation therapy. This included the delivery of optimal dose of radiation, resulting in maximum tumor control while guarding the pivotal parts of the brain such as brainstem and optic nerves.

Segment Review

The image-guided radiation therapy market is segmented int%li%product, procedure, end user, and region. On the basis of product, the market is divided int%li%4D RT, LINAC, MRI-guided radiotherapy, portal imaging, and CT scanning. By procedure, it is classified int%li%IMRT (intensity modulation radiation therapy), stereotactic therapy, particle therapy, and others. Depending on end user, it is categorized int%li%hospitals, independent radiotherapy centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product, the LINAC segment dominates the market.

By procedure, the IMRT (intensity modulation radiation therapy) segment is the leader in the market.

Region wise, North America is projected t%li%be the highest revenue generator by 2033.

Competition Analysis

The major players operating in the global image-guided radiation therapy market include Varian Medical Systems, Inc., Elekta AB, Accuray Incorporated, ViewRay, Inc., Siemens Healthineers AG, Hitachi, Ltd, Brainlab AG, MEVION MEDICAL SYSTEMS, INC., C-Rad AB, Sumitom%li%Heavy Industries, Ltd., and Philips Healthcare. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships t%li%strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk t%li%the sales executive t%li%know more)

• Additional company profiles with specific t%li%client's interest

Key Market Segments

By Product

• 4D RT
• LINAC
• MRI-guided Radiotherapy
• Portal Imaging
• CT Scanning

By Procedure

• IMRT (intensity modulation radiation therapy)
• Stereotactic Therapy
• Particle Therapy
• Others

By End User

• Hospitals
• Independent Radiotherapy Centers
• Others

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• France
• Germany
• Italy
• Spain
• UK
• Rest of Europe
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific
• LAMEA
• Brazil
• South Africa
• Saudi Arabia
• Rest of LAMEA
• Key Market Players
• Varian Medical Systems, Inc.
• Elekta AB, Accuray Incorporated
• ViewRay, Inc.
• Siemens Healthineers AG
• Hitachi, Ltd
• Brainlab AG
• MEVION MEDICAL SYSTEMS, INC.
• C-Rad AB
• Sumitom%li%Heavy Industries, Ltd.
• Philips Healthcare

Contents

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
  1.4.1. Primary Research
  1.4.2. Secondary Research
  1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
  3.2.1. Top Investment Pockets
  3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
  3.3.1. Bargaining Power of Suppliers
  3.3.2. Threat of New Entrants
  3.3.3. Threat of Substitutes
  3.3.4. Competitive Rivalry
  3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
  3.4.1. Drivers
  3.4.2. Restraints
  3.4.3. Opportunities

CHAPTER 4: LIPID NANOPARTICLES MARKET, BY TYPE

4.1. Market Overview
  4.1.1 Market Size and Forecast, By Type
4.2. Solid Lipid Nanoparticles
  4.2.1. Key Market Trends, Growth Factors and Opportunities
  4.2.2. Market Size and Forecast, By Region
  4.2.3. Market Share Analysis, By Country
4.3. Nanostructured Lipid Carriers
  4.3.1. Key Market Trends, Growth Factors and Opportunities
  4.3.2. Market Size and Forecast, By Region
  4.3.3. Market Share Analysis, By Country
4.4. Others
  4.4.1. Key Market Trends, Growth Factors and Opportunities
  4.4.2. Market Size and Forecast, By Region
  4.4.3. Market Share Analysis, By Country

CHAPTER 5: LIPID NANOPARTICLES MARKET, BY APPLICATION

5.1. Market Overview
  5.1.1 Market Size and Forecast, By Application
5.2. Therapeutics
  5.2.1. Key Market Trends, Growth Factors and Opportunities
  5.2.2. Market Size and Forecast, By Region
  5.2.3. Market Share Analysis, By Country
5.3. Research
  5.3.1. Key Market Trends, Growth Factors and Opportunities
  5.3.2. Market Size and Forecast, By Region
  5.3.3. Market Share Analysis, By Country

CHAPTER 6: LIPID NANOPARTICLES MARKET, BY END USER

6.1. Market Overview
  6.1.1 Market Size and Forecast, By End User
6.2. Pharmaceutical And Biotechnology Companies
  6.2.1. Key Market Trends, Growth Factors and Opportunities
  6.2.2. Market Size and Forecast, By Region
  6.2.3. Market Share Analysis, By Country
6.3. Academic And Research Institutes
  6.3.1. Key Market Trends, Growth Factors and Opportunities
  6.3.2. Market Size and Forecast, By Region
  6.3.3. Market Share Analysis, By Country
6.4. Others
  6.4.1. Key Market Trends, Growth Factors and Opportunities
  6.4.2. Market Size and Forecast, By Region
  6.4.3. Market Share Analysis, By Country

CHAPTER 7: LIPID NANOPARTICLES MARKET, BY REGION

7.1. Market Overview
  7.1.1 Market Size and Forecast, By Region
7.2. North America
  7.2.1. Key Market Trends and Opportunities
  7.2.2. Market Size and Forecast, By Type
  7.2.3. Market Size and Forecast, By Application
  7.2.4. Market Size and Forecast, By End User
  7.2.5. Market Size and Forecast, By Country
  7.2.6. U.S. Lipid Nanoparticles Market
    7.2.6.1. Market Size and Forecast, By Type
    7.2.6.2. Market Size and Forecast, By Application
    7.2.6.3. Market Size and Forecast, By End User
  7.2.7. Canada Lipid Nanoparticles Market
    7.2.7.1. Market Size and Forecast, By Type
    7.2.7.2. Market Size and Forecast, By Application
    7.2.7.3. Market Size and Forecast, By End User
  7.2.8. Mexico Lipid Nanoparticles Market
    7.2.8.1. Market Size and Forecast, By Type
    7.2.8.2. Market Size and Forecast, By Application
    7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
  7.3.1. Key Market Trends and Opportunities
  7.3.2. Market Size and Forecast, By Type
  7.3.3. Market Size and Forecast, By Application
  7.3.4. Market Size and Forecast, By End User
  7.3.5. Market Size and Forecast, By Country
  7.3.6. Germany Lipid Nanoparticles Market
    7.3.6.1. Market Size and Forecast, By Type
    7.3.6.2. Market Size and Forecast, By Application
    7.3.6.3. Market Size and Forecast, By End User
  7.3.7. France Lipid Nanoparticles Market
    7.3.7.1. Market Size and Forecast, By Type
    7.3.7.2. Market Size and Forecast, By Application
    7.3.7.3. Market Size and Forecast, By End User
  7.3.8. UK Lipid Nanoparticles Market
    7.3.8.1. Market Size and Forecast, By Type
    7.3.8.2. Market Size and Forecast, By Application
    7.3.8.3. Market Size and Forecast, By End User
  7.3.9. Italy Lipid Nanoparticles Market
    7.3.9.1. Market Size and Forecast, By Type
    7.3.9.2. Market Size and Forecast, By Application
    7.3.9.3. Market Size and Forecast, By End User
  7.3.10. Spain Lipid Nanoparticles Market
    7.3.10.1. Market Size and Forecast, By Type
    7.3.10.2. Market Size and Forecast, By Application
    7.3.10.3. Market Size and Forecast, By End User
  7.3.11. Rest of Europe Lipid Nanoparticles Market
    7.3.11.1. Market Size and Forecast, By Type
    7.3.11.2. Market Size and Forecast, By Application
    7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
  7.4.1. Key Market Trends and Opportunities
  7.4.2. Market Size and Forecast, By Type
  7.4.3. Market Size and Forecast, By Application
  7.4.4. Market Size and Forecast, By End User
  7.4.5. Market Size and Forecast, By Country
  7.4.6. Japan Lipid Nanoparticles Market
    7.4.6.1. Market Size and Forecast, By Type
    7.4.6.2. Market Size and Forecast, By Application
    7.4.6.3. Market Size and Forecast, By End User
  7.4.7. China Lipid Nanoparticles Market
    7.4.7.1. Market Size and Forecast, By Type
    7.4.7.2. Market Size and Forecast, By Application
    7.4.7.3. Market Size and Forecast, By End User
  7.4.8. India Lipid Nanoparticles Market
    7.4.8.1. Market Size and Forecast, By Type
    7.4.8.2. Market Size and Forecast, By Application
    7.4.8.3. Market Size and Forecast, By End User
  7.4.9. Australia Lipid Nanoparticles Market
    7.4.9.1. Market Size and Forecast, By Type
    7.4.9.2. Market Size and Forecast, By Application
    7.4.9.3. Market Size and Forecast, By End User
  7.4.10. South Korea Lipid Nanoparticles Market
    7.4.10.1. Market Size and Forecast, By Type
    7.4.10.2. Market Size and Forecast, By Application
    7.4.10.3. Market Size and Forecast, By End User
  7.4.11. Rest of Asia-Pacific Lipid Nanoparticles Market
    7.4.11.1. Market Size and Forecast, By Type
    7.4.11.2. Market Size and Forecast, By Application
    7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
  7.5.1. Key Market Trends and Opportunities
  7.5.2. Market Size and Forecast, By Type
  7.5.3. Market Size and Forecast, By Application
  7.5.4. Market Size and Forecast, By End User
  7.5.5. Market Size and Forecast, By Country
  7.5.6. Brazil Lipid Nanoparticles Market
    7.5.6.1. Market Size and Forecast, By Type
    7.5.6.2. Market Size and Forecast, By Application
    7.5.6.3. Market Size and Forecast, By End User
  7.5.7. Saudi Arabia Lipid Nanoparticles Market
    7.5.7.1. Market Size and Forecast, By Type
    7.5.7.2. Market Size and Forecast, By Application
    7.5.7.3. Market Size and Forecast, By End User
  7.5.8. South Africa Lipid Nanoparticles Market
    7.5.8.1. Market Size and Forecast, By Type
    7.5.8.2. Market Size and Forecast, By Application
    7.5.8.3. Market Size and Forecast, By End User
  7.5.9. Rest of LAMEA Lipid Nanoparticles Market
    7.5.9.1. Market Size and Forecast, By Type
    7.5.9.2. Market Size and Forecast, By Application
    7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. ABP Biosciences, LLC.
  9.1.1. Company Overview
  9.1.2. Key Executives
  9.1.3. Company Snapshot
  9.1.4. Operating Business Segments
  9.1.5. Product Portfolio
  9.1.6. Business Performance
  9.1.7. Key Strategic Moves and Developments
9.2. Merck KGaA
  9.2.1. Company Overview
  9.2.2. Key Executives
  9.2.3. Company Snapshot
  9.2.4. Operating Business Segments
  9.2.5. Product Portfolio
  9.2.6. Business Performance
  9.2.7. Key Strategic Moves and Developments
9.3. Cytiva
  9.3.1. Company Overview
  9.3.2. Key Executives
  9.3.3. Company Snapshot
  9.3.4. Operating Business Segments
  9.3.5. Product Portfolio
  9.3.6. Business Performance
  9.3.7. Key Strategic Moves and Developments
9.4. CD Bioparticles
  9.4.1. Company Overview
  9.4.2. Key Executives
  9.4.3. Company Snapshot
  9.4.4. Operating Business Segments
  9.4.5. Product Portfolio
  9.4.6. Business Performance
  9.4.7. Key Strategic Moves and Developments
9.5. CordenPharma
  9.5.1. Company Overview
  9.5.2. Key Executives
  9.5.3. Company Snapshot
  9.5.4. Operating Business Segments
  9.5.5. Product Portfolio
  9.5.6. Business Performance
  9.5.7. Key Strategic Moves and Developments
9.6. Precigenome LLC.
  9.6.1. Company Overview
  9.6.2. Key Executives
  9.6.3. Company Snapshot
  9.6.4. Operating Business Segments
  9.6.5. Product Portfolio
  9.6.6. Business Performance
  9.6.7. Key Strategic Moves and Developments
9.7. Beam Therapeutics
  9.7.1. Company Overview
  9.7.2. Key Executives
  9.7.3. Company Snapshot
  9.7.4. Operating Business Segments
  9.7.5. Product Portfolio
  9.7.6. Business Performance
  9.7.7. Key Strategic Moves and Developments
9.8. Acuitas Therapeutics.
  9.8.1. Company Overview
  9.8.2. Key Executives
  9.8.3. Company Snapshot
  9.8.4. Operating Business Segments
  9.8.5. Product Portfolio
  9.8.6. Business Performance
  9.8.7. Key Strategic Moves and Developments
9.9. Helix Biotech, Inc.
  9.9.1. Company Overview
  9.9.2. Key Executives
  9.9.3. Company Snapshot
  9.9.4. Operating Business Segments
  9.9.5. Product Portfolio
  9.9.6. Business Performance
  9.9.7. Key Strategic Moves and Developments
9.10. Genevant Sciences Corporation
  9.10.1. Company Overview
  9.10.2. Key Executives
  9.10.3. Company Snapshot
  9.10.4. Operating Business Segments
  9.10.5. Product Portfolio
  9.10.6. Business Performance
  9.10.7. Key Strategic Moves and Developments